Loading clinical trials...

Early Management Strategies of Acute Heart Failure for Patients With NSTEMI | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

NCT03189901•Qilu Hospital of Shandong University

Summary

There are always poor outcomes in patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute heart failure(AHF).Levosimendan is recommended in many clinical trials of heart failure and Chinese heart failure guidelines. As a result, the investigators form a hypothesis that when patients with AMI combined with elevated BNP/NT-proBNP level are in conditions before AHF, to use levosimendan may reduces the risk of heart failure and improve the outcome.

Eligibility

Age

18 - 74 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients diagnosed with NSTEMI in outpatient service or admitted to hospital;
•2. Patients with an elevated NT-proBNP level;
•3. Patients sign the informed consent;

Exclusion Criteria

•1. Patients with hypotension(systolic pressure\<100mmHg), creatinine clearance rate\<30ml/min or be allergic to levosimendan;
•2. Patients whose heart function grade of Killip are Level III\~IV;
•3. Patients suffering from hepatic failure, renal failure or other diseases which may shorten the lifetime to 6 months(for example tumor);
•4. Patients with valvular heart diseases influencing haemodynamics, hypertrophic or restricted cardiomyopathy, constrictive pericarditis, severe pulmonary hypertension or myocarditis;
•5. Patients with serum potassium level\<3.5mmol/L;
•6. Pregnant and lactating women;
•7. Patients participating in other relevant clinical studies.

Locations (14)

Anhui Provincial Hospital

Hefei, Anhui, China

Beijing China-Japan Friendship Hospital

Beijing, Beijng, China

Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Shengjing Hospital Affiliated to China Medical University

Shenyang, Liaoning, China

Shengli Oilfield Central Hospital

Dongying, Shandog, China

Binzhou People's Hospital

Binzhou, Shandong, China

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Jinan, Shandong, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Tai'an Central Hospital

Tai’an, Shandong, China

Weifang People's Hospital

Weifang, Shandong, China

Key Dates

Start Date

July 1, 2017

Primary Completion Date

December 31, 2021

Completion Date

December 31, 2021

Last Updated

July 19, 2021

Enrollment

470

ESTIMATED participants

Conditions

Early ManagementAcute Heart FailureNSTEMI - Non-ST Segment Elevation MI

Interventions

Regular management+Levosimendan

DRUG

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

RECRUITING

Respiratory Virus Infections in Acute Heart Failure

NCT06967441

Acute Heart Failure Syndrome

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 19, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

Inclusion Criteria

Exclusion Criteria

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Respiratory Virus Infections in Acute Heart Failure

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Digoxin After Acute Heart Failure

MRI Assessment of Pulmonary Edema in Acute Heart Failure